Boryung wins patent nullification trial over oxaliplatin

A patent trial board said it had ruled against a liquid form of Eloxatin patent owned by Sanofi-Aventis in its nullification trial which had been sought by Borung Pharm on April, 2006.

The board said in its ruling that Eloxatin patent is based on well-known materials and processes without any novelty.

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and ca...